Strategic Grants Ionica Sciences has a track record of securing SBIR grants and DARPA-funded efforts, with substantial prior SBIR funding and ongoing government-backed programs. This indicates potential for programmatic partnerships, contract-focused collaborations, and multi-year funding opportunities for sensor and assay development.

High Sensitivity Current focus on detecting biologically relevant molecules at pg/mL levels positions Ionica as a candidate for high-sensitivity diagnostic platforms. Sales opportunities exist in partnerships or co-development contracts with government labs, healthcare providers, and окуpational health customers seeking rapid, low-prep assays.

Academic Alliances Active collaboration with Cornell University and City College of New York suggests existing access to academic channels and pilot opportunities. Leverage these ties to propose joint development agreements, pilot programs, and early-access trials for new spectroscopy-based detection methods.

Lyme and Pathogen Focus Past partnerships aimed at Lyme disease diagnostics indicate a market niche for infectious disease assays and tick-borne pathogen detection. Potential sales avenues include collaborations with disease surveillance programs, diagnostic labs, and nonprofit organizations focused on tick-borne diseases.

Early Commercial Readiness With a goal to bring an FDA-approved assay to market within 3-5 years, there is an opportunity to engage early customers for requirements gathering, advisory roles, and pre-market validation partnerships to accelerate regulatory milestones and market entry.